NASDAQ:ZGNX - Zogenix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$46.99 -0.07 (-0.15 %)
(As of 02/17/2019 12:43 PM ET)
Previous Close$46.99
Today's Range$46.37 - $48.12
52-Week Range$33.43 - $62.75
Volume358,393 shs
Average Volume425,156 shs
Market Capitalization$1.97 billion
P/E Ratio-11.69
Dividend YieldN/A
Beta2.05
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ZGNX
CUSIP98978L10
Phone510-550-8300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.82 million
Book Value$8.80 per share

Profitability

Net Income$-126,810,000.00

Miscellaneous

Employees68
Market Cap$1.97 billion
OptionableOptionable

Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) issued its quarterly earnings results on Monday, August, 6th. The company reported ($0.82) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.88) by $0.06. During the same quarter in the previous year, the firm posted ($0.90) earnings per share. View Zogenix's Earnings History.

When is Zogenix's next earnings date?

Zogenix is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Zogenix.

What price target have analysts set for ZGNX?

9 equities research analysts have issued twelve-month price objectives for Zogenix's shares. Their forecasts range from $60.00 to $116.00. On average, they anticipate Zogenix's share price to reach $73.00 in the next twelve months. This suggests a possible upside of 55.4% from the stock's current price. View Analyst Price Targets for Zogenix.

What is the consensus analysts' recommendation for Zogenix?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zogenix.

What are Wall Street analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:
  • 1. According to Zacks Investment Research, "Zogenix is a specialty biopharmaceutical company focused on developing therapies for patients with rare central nervous system conditions that have limited or no treatment options. The company is currently pursuing two therapies targeting the Dravet Syndrome and the Lennox-Gastaut Syndrome. " (2/16/2019)
  • 2. Mizuho analysts commented, "We note that the competitor product Epidiolex has launched in the U.S. on Nov. 1, 2018. We believe with a superior product profile, we believe Fintepla could become the standard of care in Dravet patients. See our prior note (available here) for additional details. Potential approval of Fintepla remains the key catalyst for Zogenix in 2019. If FDA approved, Fintepla could launch in the U.S. in 3Q19. An AdComm meeting is possible in 2019 prior to the potential FDA approval." (2/6/2019)

Has Zogenix been receiving favorable news coverage?

News articles about ZGNX stock have trended negative this week, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zogenix earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.

Who are some of Zogenix's key competitors?

Who are Zogenix's key executives?

Zogenix's management team includes the folowing people:
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 60)
  • Mr. Roger L. Hawley B.S., Co-Founder & Director (Age 66)
  • Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 51)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 57)
  • Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 55)

Who are Zogenix's major shareholders?

Zogenix's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.54%), Bank of New York Mellon Corp (5.79%), RA Capital Management LLC (5.68%), venBio Select Advisor LLC (4.71%), Great Point Partners LLC (2.38%) and Eagle Asset Management Inc. (2.24%). Company insiders that own Zogenix stock include Bradley S Galer, Cam L Garner, Erle T Mast, Gail M Farfel, Life Sciences Maste Perceptive, Renee P Tannenbaum, Roger Hawley and Stephen J Farr. View Institutional Ownership Trends for Zogenix.

Which institutional investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Broadfin Capital LLC, Bank of New York Mellon Corp, Polar Capital LLP, Barclays PLC, Emerald Advisers LLC, Two Sigma Advisers LP and BlackRock Inc.. Company insiders that have sold Zogenix company stock in the last year include Cam L Garner, Erle T Mast, Gail M Farfel, Roger Hawley and Stephen J Farr. View Insider Buying and Selling for Zogenix.

Which institutional investors are buying Zogenix stock?

ZGNX stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Westfield Capital Management Co. LP, venBio Select Advisor LLC, RA Capital Management LLC, Dimensional Fund Advisors LP, Eversept Partners LP, Candriam Luxembourg S.C.A. and Samlyn Capital LLC. Company insiders that have bought Zogenix stock in the last two years include Bradley S Galer, Life Sciences Maste Perceptive and Renee P Tannenbaum. View Insider Buying and Selling for Zogenix.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $46.99.

How big of a company is Zogenix?

Zogenix has a market capitalization of $1.97 billion and generates $9.82 million in revenue each year. The company earns $-126,810,000.00 in net income (profit) each year or ($4.02) on an earnings per share basis. Zogenix employs 68 workers across the globe.

What is Zogenix's official website?

The official website for Zogenix is http://www.zogenix.com.

How can I contact Zogenix?

Zogenix's mailing address is 5858 Horton Street Suite 455, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]


MarketBeat Community Rating for Zogenix (NASDAQ ZGNX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  346 (Vote Outperform)
Underperform Votes:  239 (Vote Underperform)
Total Votes:  585
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe ZGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel